Successful Exhibition of YHLO's High-Sensitivity Cardiac Troponin I (hs-cTnI) Poster at ADLM 2024

YHLO Biotech is pleased to announce the successful presentation of its high-sensitivity cardiac troponin I (hs-cTnI) poster at the recent Association for Diagnostics & Laboratory Medicine (ADLM) exhibition. The poster, which showcased the latest advancements in cardiac biomarker diagnostics, received considerable attention from leading industry experts and researchers.?

Highlighting Exceptional Performance and Validation Data

The presented poster highlighted several critical aspects of the hs-cTnI assay's performance, particularly focusing on its validation at the National Center for Cardiovascular Diseases & Fuwai Hospital. The data underscored the assay's precision and reliability, with a special emphasis on its analytical characteristics and gender-specific 99th percentile upper reference limits (URLs).

Comprehensive Validation Studies

The validation studies involved a cohort of 650 healthy adults from South China, including 304 males and 346 females, to determine the 99th percentile URLs. The results demonstrated that the 99th percentile URL for the overall population was 9.94 ng/L (90% CI 8.23-13.64 ng/L), with males showing a higher URL of 13.47 ng/L (90% CI 8.19-17.98 ng/L) compared to females at 9.06 ng/L (90% CI 7.95-12.14 ng/L). This gender-specific differentiation is crucial for accurate clinical assessments and underscores the assay's capability to provide tailored diagnostic information.

Precision and Sensitivity

YHLO iFlash 3000 assays demonstrated remarkable precision, with coefficients of variation (CVs) well within acceptable limits. The limit of blank (LoB), limit of detection (LoD), and limit of quantitation (LoQ) were meticulously established for both assays, with LoD values of 0.37 ng/L for iFlash 3000 and 0.44 ng/L for iStar 500, reinforcing the assays' high sensitivity.

?

Collaborative Research Initiatives

YHLO Biotech's ongoing collaboration with top-tier cardiovascular research institutions, including the prestigious Fuwai Hospital, exemplifies its commitment to advancing cardiac diagnostics. YHLO also involved in multi-center research studies and national key research and development projects under China's "14th Five-Year Plan". These initiatives aim to push the boundaries of diagnostic innovation and improve clinical outcomes for patients with cardiovascular diseases.?

Future Prospects

Looking ahead, YHLO Biotech plans to expand its academic and clinical collaborations globally. YHLO's high-sensitivity cardiac troponin I (hs-cTnI) products, verified by leading institutions such as Fuwai Hospital, are set to play a pivotal role in optimizing the diagnosis and treatment processes for cardiovascular diseases. By leveraging cutting-edge technology and fostering international partnerships, YHLO is poised to make significant contributions to the field of IVD.

?

About YHLO Biotech

YHLO Biotech is a leading manufacturer in the field of IVD, dedicated to providing innovative solutions for clinical laboratories worldwide. With a strong focus on research and development, YHLO offers a wide range of diagnostic products and services that meet the highest standards of quality and performance. The company's commitment to excellence is reflected in its ongoing collaborations with renowned research institutions and its active participation in global healthcare initiatives.

For more information about YHLO's hs-cTnI poster at ADLM 2024, please visit https://www.abstractsonline.com/pp8/#!/20594/presentation/125 .